Table 11.
Analysis of serum anti-palivizumab antibodies (FAS).
| Time point | Category | (N = 23) |
|
|---|---|---|---|
| n | (%) | ||
| 30 days after the fourth dose | <30 | 22 | (95.65) |
| 30 days after the fifth dose | <30 | 2 | (8.70) |
FAS, full analysis set. Data are shown in [μg/mL] unless otherwise stated.